Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.

You may also be interested in...



U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data

It is going to take time for the public and policymakers to get comfortable with the idea of U.S. FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.

FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data

It is going to take time for the public and policymakers to get comfortable with the idea of FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.

FDA’s Latest Communication Project Is Grant Opportunity For Non-profits

The agency is offering a modest $200,000 grant to piggyback on efforts by non-profit groups to “foster better understanding of the work of CDER.”

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel